 SAINT LAURENT, Quebec, May 12, 2021 GLOBE NEWSWIRE -- IntelGenx Corp. TSX-V:IGX OTCQB:IGXT IntelGenx, a leader in pharmaceutical films, today announced that it has entered into a second feasibility agreement the SFA with ATAI Life Sciences AG atai, a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, for the development of novel formulations of Salvinorin A, a naturally occurring psychedelic compound being developed for the treatment of treatment-resistant depression and other indications. 